| | Choosing the Best Sample Collection Device for DTC Testing With at-home testing on the rise, there has been an increasing number of sample collection devices on the market. As a key component of the testing kit, it’s crucial to find the right device for your DTC company. Find out how to choose the best sample collection device with this free guide. Download Now. |
Big pharma resisting temptation for biotech M&A spree until prices drop further Intellia puts pedal to the metal as 3 new candidates prepped for clinic BioCryst's voluntary pause turns FDA-hold as investigation reveals likely culprit behind safety signals Sponsored: Progress with Promise with Ibex® Design’s 11-month DNA to IND guarantee Jazz flexes deal chops, paying Sumitomo $50M for ex-Asia rights to early-phase narcolepsy prospect Sponsored: With the makings of a hub, NYC primed to be life sciences leader BerGenBio shifts focus from COVID—to COVID in new business strategy update Bavarian Nordic's COVID-19 vaccine holds up against omicron in phase 2, fueling pivotal booster push FDA rebukes Pfizer CEO's suggestion to take more Paxlovid if COVID-19 symptoms return Curebase attracts Gilead as backer in $40M financing to expand business Change of heart: Antibody therapy reverses 'incurable' pulmonary hypertension in mice On a roll, AstraZeneca's Ultomiris hits goal in rare autoimmune disease Study: Only small amount of docs in some Medicaid managed care networks offer care to Medicaid patients FDA clears Abbott test to spot 4 STIs at once amid soaring case rates Asia-Pacific CRO Novotech makes US play with NCGS acquisition Featured Story | By James Waldron Plunging valuations may be forcing biotechs to lay off staff and strip back their pipelines, but Big Pharma is not yet tempted to go on an M&A spree. Judging by first-quarter earnings calls over the past two weeks, CEOs of many of the world’s pharma giants believe biotech prices still have a way to drop before they became irresistible acquisitions. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Intellia has three candidates from its gene editing and cell therapy platform headed to a clinic near you in the next year or so. The company previewed its next steps in a first-quarter earnings call Thursday morning, detailing recent clinical activities and the upcoming data readouts that will define the CRISPR biotech for years to come. read more By Max Bayer A voluntary pause for BioCryst Pharmaceuticals' complement-mediated disease therapy has been upgraded to a partial FDA clinical hold, but the biotech now believes it has an idea of what's behind the safety signals that have ground the program to a halt. read more Sponsored By: Lonza AG Exactly what you need from your DNA to IND partner to succeed. A unique guarantee of speed and quantity, backed by Lonza’s 35 years of experience in biologics, for a fixed price. read more By Nick Paul Taylor Jazz Pharmaceuticals is continuing its double-time business development pace, with the company inking its third deal to license or divest an asset in the past five weeks. Sumitomo Pharma is the latest company to occupy the other side of the deal table, agreeing to grant Jazz rights to its narcolepsy prospect. read more Sponsored by: New York City Economic Development Corporation With a $1 billion public investment, diverse talent and science, space, and funding, NYC emerges as a global leader in life sciences. read more By Annalee Armstrong After a phase 2 fail in COVID-19 last year, BerGenBio is shifting its business strategy to focus on, well, still COVID-19. read more By Nick Paul Taylor Bavarian Nordic has evidence its COVID-19 vaccine may hold up against omicron. With a midphase trial finding antibody titers were boosted to levels associated with a high level of protection, the biopharma is pushing ahead with plans to move into a phase 3 study. read more By Zoey Becker The FDA is taking another look at Paxlovid's clinical trial results amid reports of patients suffering from relapses in COVID-19 symptoms. The agency disagrees with Pfizer CEO Albert Bourla's suggestion to take another treatment course if symptoms return. read more By Gareth Macdonald Curebase says $40 million raised through an investment round that attracted Gilead as a backer will fund platform expansion and help the CRO enter the complex interventional studies market. read more By Gabrielle Masson Scientists have blocked a molecular pathway and developed an antibody therapy that may reverse characteristics of largely untreatable pulmonary arterial hypertension, according to new study findings from patient samples and mouse models. read more By Angus Liu AstraZeneca is making new progress with its Ultomiris expansion plan. On the heels of an FDA approval, the C5 inhibitor has returned with a clinical win in a rare autoimmune disease affecting the central nervous system. read more By Robert King A new Health Affairs study finds a small amount of physicians in Medicaid managed care networks, prompting questions about state network adequacy standards. read more By Andrea Park The test was cleared by the FDA for samples collected in a healthcare setting, but Abbott also aims to bring STI screening into the home. read more By Annalee Armstrong Asia-Pacific CRO Novotech is getting into business on this side of the world with the acquisition of South Carolina-based clinical services company NCGS. read more Resources Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next Gen June 29-30, 2022 | Free Virtual Event Fierce Pharma PR & Communications Summit East July 19-20, 2022 | Jersey City, NJ Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 